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Background: The aim of this study was to evaluate the proportion of patients with ankylosing 
spondylitis maintaining clinical remission after reduction of their subcutaneous etanercept dose to 
50 mg every other week compared with that in patients receiving etanercept 50 mg weekly.
Methods: In the first phase of this randomized, prospective, follow-up study, all biologic-
naïve patients identified between January 2005 and December 2009 as satisfying the modified 
New York clinical criteria for ankylosing spondylitis treated with etanercept 50 mg weekly 
were evaluated for disease remission in January 2010. In the second phase, patients meeting 
the criteria for remission were randomized to receive subcutaneous etanercept as either 50 mg 
weekly or 50 mg every other week. The randomization allocation was 1:1. Remission was defined 
as Bath Ankylosing Spondylitis Disease Activity Index , 4, no extra-axial manifestations of 
peripheral arthritis, dactylitis, tenosynovitis, or iridocyclitis, and normal acute-phase reactants. 
The patients were assessed at baseline, at weeks 4 and 12, and every 12 weeks thereafter. The 
last visit constituted the end of the follow-up.
Results: During the first phase, 78 patients with ankylosing spondylitis (57 males and 21 females, 
median age 38 years, median disease duration 12 years) were recruited. In January 2010, after 
a mean follow-up of 25 ± 11 months, 43 (55.1%) patients achieving clinical remission were 
randomized to one of the two treatment arms. Twenty-two patients received etanercept 50 mg 
every other week (group 1) and 21 received etanercept 50 mg weekly (group 2). At the end of 
follow-up, 19 of 22 (86.3%) subjects in group 1 and 19 of 21 (90.4%) in group 2 were still in 
remission, with no significant difference between the two groups. The mean follow-up duration 
in group 1 and group 2 was 22 ± 1 months and 21 ± 1.6 months, respectively.
Conclusion: Remission of ankylosing spondylitis is possible in at least 50% of patients 
treated with etanercept 50 mg weekly. After halving of the etanercept dose, remission is main-
tained in a high percentage of patients during long-term follow-up, with important economic 
implications.
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Introduction
Ankylosing spondylitis is a chronic inflammatory disorder that occurs mainly in HLA 
B27-positive individuals, and is characterized by entheseal and synovial involve-
ment, with progressive damage and ankylosis of the spine in the majority of patients.1 
The disease is characterized by impaired production of Th1 cytokines, with a sustained 
inflammatory response characterized by elevated serum levels of tumor necrosis 
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  factor alpha (TNFα) and interleukin-6, and abundant TNFα 
mRNA in the sacroiliac joints.2,3 These immunopathological 
data provided the basis for studies evaluating the efficacy of 
anti-TNFα agents in ankylosing spondylitis.4
The clinical response in patients with ankylosing spon-
dylitis has been assessed by evaluating reduction in disease 
activity using the Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI),5 mobility using the Bath Ankylos-
ing Spondylitis Metrology Index (BASMI),6 and functional 
status by the Bath Ankylosing Spondylitis Functional Index 
(BASFI),7 and more recently by the Assessments in Anky-
losing Spondylitis Working Group (ASAS) improvement 
criteria8 and the Ankylosing Spondylitis Disease Activity 
Score.9 All these sets of response criteria evaluate the best 
response in terms of low BASDAI score (,4),5 ASAS 70 
partial response,8 and Ankylosing Spondylitis Disease Activ-
ity Score inactive disease (,1.3).9
Randomized controlled trials have provided consistent 
evidence of the efficacy of the anti-TNFα agents, including 
infliximab, etanercept, and adalimumab, in the treatment 
of ankylosing spondylitis, with a 50% reduction in disease 
activity in around 60%–70% of patients.4 Four randomized 
controlled trials have provided evidence of the efficacy and 
safety of subcutaneous etanercept 25 mg twice weekly in 
the treatment of active ankylosing spondylitis,10–13 with 
60%–80% of patients achieving an ASAS 20 response. 
Durability of the efficacy and tolerability of etanercept has 
recently been reported, with 81% of patients maintaining their 
ASAS 20 score after 192 weeks of treatment.14 Notably, in 
the same long-term evaluation, 44% of patients maintained 
remission, as assessed by an ASAS 70 partial response.
A 12-week randomized controlled trial in ankylosing spon-
dylitis in which etanercept was administered either as 50 mg 
once weekly or 25 mg twice weekly15–17 demonstrated efficacy 
and safety results comparable with those observed in rheuma-
toid arthritis.18 Like other biologics, etanercept is an expensive 
therapy with a heavy economic burden for health care systems 
in many countries. Consequently, we believed that any effective 
ethical strategy to reduce the cost with no worsening of patient 
quality of life would be of great value. Therefore, we designed 
this two-phase, randomized, prospective follow-up study to 
evaluate the proportion of patients with ankylosing spondylitis 
maintaining clinical remission after reduction of their etanercept 
dose to 50 mg subcutaneously every other week.
Materials and methods
In the first phase of this study, all biologic-naïve patients 
treated between January 2005 and December 2009 who met 
the modified New York criteria for ankylosing spondylitis19 
were given etanercept 50 mg weekly and evaluated for disease 
remission in January 2010. In the second phase, patients who 
satisfied the criteria for disease remission were randomized 
to one of the following two subcutaneous treatment arms: 
etanercept 50 mg weekly or etanercept 50 mg every other 
week. Randomization allocation was 1:1 and treatment was 
continued until disease flare-up. The local ethics committee 
reviewed and approved the study protocol. Before entering 
the trial, each patient was informed of the nature, duration, 
and purpose of the study, as well as all the potential benefits 
and drawbacks that could be expected. All participants gave 
their written informed consent.
Definitions
•	 Disease remission: patients were considered to be in 
remission if they had a BASDAI score , 4, no extra-axial 
manifestations of peripheral arthritis, dactylitis, teno-
synovitis, or anterior uveitis, and a normal erythrocyte 
sedimentation rate and C-reactive protein levels
•	 Disease flare-up: patients presenting at follow-up visits 
with BASDAI . 4 or any of the other above-mentioned 
peripheral articular and extra-articular manifestations 
independently of elevation of acute-phase reactants
•	 Dactylitis: diffuse tenderness and swelling of the entire 
digit with a sausage-like appearance
•	 Enthesitis: tenderness and swelling at sites of tendon, 
  ligament, and joint capsule insertion into bone, assessed by 
the Maastricht Ankylosing Spondylitis Enthesitis score20
•	 Inflammatory spinal pain: patients were defined as having 
inflammatory spinal pain if they met the Calin’s criteria 
for this clinical feature.21
Primary and secondary endpoints
The primary endpoint was the proportion of patients with 
ankylosing spondylitis maintaining clinical remission after 
reduction of the etanercept dose to 50 mg every other week 
compared with those continuing to receive etanercept 50 mg 
weekly. Secondary endpoints were the proportion of patients 
with ankylosing spondylitis who achieved clinical remission, 
the duration of remission after halving the etanercept dose, 
time to relapse, and the frequency of adverse events.
Treatment regimen
Patients received etanercept 50 mg in prefilled syringes for 
subcutaneous injection. Qualified personnel instructed all 
patients in correct injection technique and directly observed 
self-administration of the first dose. The drug was delivered 
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monthly to each patient in package containing four prefilled 
syringes, and all patients were instructed on how to store the 
drug protected from light at 2°C–6°C. Patients were advised 
to call the center for substitution of their drug package in 
the event of malfunction of their home refrigerator and 
consequent altered storage. In the event of relapse, patients 
reverted to using etanercept 50 mg weekly. Intra-articular and 
systemic corticosteroids and nonsteroidal anti-inflammatory 
drugs were not permitted during the study period. In the 
event of pain, the patients were allowed to take analgesics 
(acetaminophen or tramadol). None of the patients in either 
group received psychotherapy or physiotherapy.
Outcome measures
The patients were evaluated for remission as the primary 
outcome measure at enrolment and at every follow-up visit. 
Secondary outcome measures were the proportion of patients 
achieving remission at the end of the first phase of the study, 
ie, ASAS 20, 50, and 70 responses, improvement in BASDAI, 
BASMI, and BASFI scores, chest expansion, finger-to-floor 
distance, tender and swollen joint counts, number of painful 
entheses, number of digits showing dactylitis, erythrocyte 
sedimentation rate and C-reactive protein levels, and number 
and severity of adverse events.
Follow-up
Patients were followed by the same rheumatologist, and 
follow-up visits were scheduled at baseline, after one month, 
and every 3 months thereafter. Intervals between control 
visits were shortened in the event of urgent clinical problems, 
and all patients were instructed to call the center if there was 
any worsening of axial or peripheral symptoms, onset of 
extra-articular manifestations, or adverse events.
At every visit, patients had a complete physical exami-
nation including all previously listed outcome measures. 
  Routine blood examinations, including erythrocyte sedimen-
tation rate, C-reactive protein, rheumatoid factor, complete 
blood cell count with differential count, renal and liver 
function tests, and antinuclear antibodies were also carried 
out. All clinical and laboratory data were recorded in a com-
puterized patient chart.
The date of the last visit constituted the end of follow-up, 
which was extended to December 2011.
Adverse events
All patients were monitored for clinical and laboratory 
evidence of adverse events, defined as mild (transient 
and easily tolerated), moderate (subject discomfort with 
  interruption of usual activities), or severe (incapacitating or 
life-threatening).
statistical analysis
Descriptive statistics and statistical differences were calculated 
using the Statistical Package for Social Sciences version 11 
for Windows (SPSS Inc, Chicago, IL). The Wilcoxon’s 
matched-pairs signed rank test was used to measure changes 
from baseline, and the t-test for continuous variables and 
Chi-square test for nominal variables were used to calculate 
the differences between the two treatment arms. P values less 
than 0.05 were accepted as being statistically significant.
Results
From January 2005 to December 2009, 78 patients with 
ankylosing spondylitis were treated with etanercept 50 mg 
weekly. Table 1 summarizes the patient demographic and 
clinical characteristics at baseline. Etanercept was discontin-
ued in 12 (15.3%) patients, due to inefficacy in nine (11.5%) 
and adverse events in three (4%), including repeated urinary 
and upper airway infections, severe cutaneous reaction at the 
injection site, and pneumonitis in one patient each.
In January 2010, after a mean follow-up of 25 ± 11 months, 
43 (55.1%) patients were in clinical remission. Of these 
patients, 22 were randomized to receive etanercept 50 mg 
every other week and 21 to 50 mg weekly. The results are 
shown in Table 2. As expected, the two groups did not differ 
regarding their demographic and clinical characteristics. At 
the end of follow-up, 19 of 22 (86.3%) patients treated with 
etanercept 50 mg every other week and 19 of 21 (90.4%) 
receiving etanercept 50 mg weekly were still in remission, 
with no statistically significant difference between the two 
groups.
Disease relapse occurred after a mean interval of 
8 ± 3.2 months in the etanercept 50 mg every other week 
group and after 10 ± 1.1 months in the etanercept 50 mg 
weekly group; this difference was not statistically significant. 
As dictated by the protocol, escalation of the etanercept dose 
to 50 mg weekly was prescribed for patients who relapsed 
on etanercept 50 mg every other week, and they entered 
remission again after a mean interval of 5.1 ± 2.4 months. 
Two patients who had a disease flare-up on etanercept 50 mg 
weekly were switched to a different anti-TNFα agent.
Regarding tolerability and safety, mild injection site 
reactions were documented in three of 22 (13.6%) patients in 
group 1 and four of 21 (19%) patients in group 2, along with 
urinary infections in two (9%) patients and one (4.7%) patient, 
upper airways infections in seven (31.8%) and five (23.8%), 
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slightly elevated liver enzymes in one (4.5%) and two (9.5%), 
in group 1 and group 2, respectively, with no severe adverse 
event requiring interruption of etanercept therapy. Antinuclear 
antibody positivity was observed in one (4.7%) patient in 
group 1 and two (9%) patients in group 2, but no patient 
developed signs or symptoms of lupus-like syndrome.
Discussion
To the best of our knowledge, only three studies to date 
have focused on maintenance of clinical remission after 
reduction of the etanercept dose in patients with ankylosing 
spondylitis. In the first one,22 reduction of the etanercept 
dose to 25 mg weekly after a 12-week induction period 
with etanercept 50 mg weekly was effective for maintain-
ing remission in 17 (94.4%) of 18 patients with ankylosing 
spondylitis over a 6-month follow-up period. Remission 
was defined as a 50% reduction in BASDAI score and 
normal levels of acute-phase reactants. In the second ret-
rospective study, reported by the same group,23 the clinical 
response at 21 months was maintained in 109 patients with 
ankylosing spondylitis despite progressive lengthening of 
the etanercept dosing interval to 12.1 ± 7.0 days. Finally, 
in a prospective study from Spain,24 the etanercept dose 
was reduced in 16 (31.4%) of 51 patients with ankylosing 
spondylitis who were still in remission after a mean treat-
ment duration of 17 ± 12 months. Remission was defined as 
a BASDAI score , 4 and normal C-reactive protein levels. 
The etanercept dose was reduced to 25 mg weekly in four 
(25%) patients, 25 mg every 10 days in one patient (6.3%), 
25 mg every other week in two patients, 50 mg every 8 days 
in three patients (18.7%), and 50 mg every 10 days in the 
remaining six patients (37.5%). This treatment regimen 
was not changed and all patients maintained their remission 
through a mean follow-up of 26.1 ± 21 months.
Similar attempts to reduce the etanercept dose have also 
been reported in patients with ankylosing spondylitis treated 
with infliximab, with conflicting results. Reduction of the 
infliximab dose to 3 mg/kg was not effective in a clinical 
series of 12 patients with ankylosing spondylitis, 16 with 
axial psoriatic arthritis, and two with undifferentiated spon-
dyloarthritis and prevalent axial involvement.25 In keeping 
with a previous Canadian report,26 a study from the United 
Kingdom reported that an infliximab dose of 3 mg/kg was 
effective in suppressing signs and symptoms of ankylos-
ing spondylitis in 19 of 22 (86.3%) patients.27 Discussing 
their results, the authors underscored the relevant economic 
implications of reduction of the infliximab dose in terms 
of both direct and indirect cost savings, including hospital 
attendance and nursing time.
Unlike in rheumatoid arthritis, anti-TNF therapy does 
not seem to inhibit radiographic progression of ankylosing 
spondylitis,28 so clinical remission was defined in our study 
in terms of suppression of signs and symptoms of the dis-
ease, with 43 (55.1%) of 78 patients achieving this result on 
etanercept 50 mg weekly after a mean treatment duration of 
9.0 ± 4.9 months.
Confirming the findings of other studies of reduction of 
the etanercept dose in ankylosing spondylitis,22–24 no signifi-
cant increase in disease flare-up was recorded in our random-
ized study of 43 patients treated with etanercept 50 mg every 
Table 1 Demographic and clinical characteristics of 78 patients 
with ankylosing spondylitis at baseline and at the end of follow-up 
in December 2009
Patients Baseline End of  
follow-up
P
Total (n) 78 66
Female (n, %) 
Male (n, %)
21 (28%) 
57 (72%)
16 (24%) 
50 (76%)
Median age at study entry (years) 38
Mean disease duration (years) 12
EsR (mm/hour) 30.1 ± 16.3 12.3 ± 4.2 ,0.001
CRP (mg/dL) 1.9 ± 1.1 0.34 ± 0.23 ,0.001
Patients with elevated EsR (n, %) 36 (46.1%) 3 (4.5%)
Patients with elevated CRP (n, %) 40 (51.2%) 5 (7.6%)
B27+ (n, %) 72 (92.3%)
Peripheral arthritis (n, %) 15 (19.2%) 1 (1.5%)
Enthesitis/dactylitis (n, %) 28 (35.8%) 7 (10.6%)
Iridocyclitis at onset  
or complicating  
the clinical course (n, %)
13 (16.6%)
BAsDAI 6.9 ± 1.9 3.0 ± 1.6 ,0.001
BAsFI 5.5 ± 1.7 2.8 ± 1.3 ,0.001
BAsMI 4.8 ± 1.1 3.1 ± 1.5 ,0.001
Modified Schober test (cm) 4.9 ± 1.56 3.1 ± 1.87 ,0.001
Fingertip to floor distance (cm) 15.3 ± 6.6 7.6 ± 2.1 ,0.001
Chest expansion (cm) 3.3 ± 0.28 3.96 ± 0.14 ,0.001
Overall drug discontinuation 
and reason (n, %) 
No response 
Adverse events*
12 (15.3%) 
 
9 (11.5%) 
3 (4.0%)
AsAs 20 (n, %) 
AsAs 50 (n, %) 
AsAs 70 (n, %)
66 (100%) 
48 (72.7) 
43 (55.1)
Remission (patients, n, %) 43 (55.1%)
Time to remission (months) 9 ± 4.9
Follow-up duration (months) 25 ± 11
Notes: Data are expressed as the mean ± sD except where otherwise indicated. 
*As reported in text. 
Abbreviations:  AsAs,  Assessments  in  Ankylosing  spondylitis;  BAsDAI,  Bath 
Ankylosing spondylitis Disease Activity Index; BAsFI, Bath Ankylosing spondylitis 
Functional Index; BAsMI, Bath Ankylosing spondylitis Metrology Index; sD, stan-
dard deviation; EsR, erythrocyte sedimentation rate (Westergren); CRP, C-reactive 
protein.
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other week versus etanercept 50 mg weekly over a mean 
long-term follow-up of 22 ± 1.1 months.
Beyond the potential advantages in terms of compliance 
with therapy and reduced drug exposure risk, data from other 
clinical series22–24 along with our results seem to indicate a 
new therapeutic option for the management of patients with 
ankylosing spondylitis. Indeed, halving of the etanercept dose 
after achieving remission constitutes an ethical therapeutic 
strategy with relevant economic implications. As with other 
anti-TNF agents, etanercept is an expensive therapy, with an 
estimated yearly cost of around €15,000 per patient. Data 
from randomized clinical trials10–14 show that around half 
of the patients with ankylosing spondylitis who are treated 
with etanercept 50 mg weekly achieve suppression of dis-
ease activity. Therefore, we suggest that reduction of the 
etanercept dose to 50 mg every other week in these patients 
would allow a consistent reduction of economic burden 
with no worsening of patient health status. As a direct con-
sequence of our trial, we calculated a consistent cost saving 
of around €260,000 (€7500 per patient per year multiplied 
by 19 patients for 22 months).
Conclusion
Our results indicate that suppression of disease activity 
is possible in more than 50% of patients with ankylosing 
spondylitis treated with etanercept 50 mg weekly. Notably, 
after halving of the etanercept dose, a high percentage of 
patients maintain remission during long-term follow-up, 
with no significant differences from those continuing the 
standard etanercept dose. The sustained disease remission 
after reduction of the etanercept dose suggests that this 
therapeutic strategy can be applied in clinical practice, with 
important advantages in terms of drug exposure risk, patient 
compliance with therapy, and cost savings.
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